title: Long-term clinical course of decompensated alcoholic cirrhosis: a prospective study of 165 patients.
abstract: BACKGROUND
  Prognosis of decompensated alcoholic cirrhosis is based mainly on studies that included patients with different severities of liver disease and did not recognize either hepatitis C virus epidemic or changes in clinical management of cirrhosis.
  
  
  OBJECTIVE
  To define the long-term course after the first hepatic decompensation in alcoholic cirrhosis.
  
  
  METHODS
  Prospective inclusion at the start point of decompensated cirrhosis of 165 consecutive patients with alcoholic cirrhosis without known hepatocellular carcinoma hospitalized from January 1998 to December 2001 was made. Follow-up was maintained until death or the end of the observation period (April 1, 2010).
  
  
  RESULTS
  The patients were followed for 835.75 patient years. Median age was 56 years (95% confidence interval: 54-58). Baseline Child-Pugh score was 9 (95% CI: 8-9), and model for end-stage liver disease (MELD) was 13.8 (95% CI: 12.5-14.7). Ascites was the most frequent first decompensation (51%). During follow-up, 99 (60%) patients were abstinent, hepatocellular carcinoma developed in 18 (11%) patients, and 116 patients died (70%). Median overall survival was 61 months (95% CI: 48-74). Median survival probability after onset of hepatic encephalopathy (HE) was only 14 months (95% CI: 5-23). Age, baseline MELD, albumin, development of HE, and persistence of alcohol use were independently correlated with mortality.
  
  
  CONCLUSIONS
  Patients with alcoholic cirrhosis show a high frequency of complications. The low mortality rate in our cohort of patients probably reflects the improvement in the management of patients with cirrhosis; it is mainly influenced by baseline MELD, age, HE development, and continued abstinence. Patients who develop HE should be considered for hepatic transplantation.
authors.affiliation: Departament of Gastroenterology, Liver Unit, Hospital Universitari Germans Trias i Pujol, Spain. marcoalgo@gmail.com
authors.forename: Marco Antonio
authors.initials: MA
authors.lastname: Alvarez
authors.forename: Isabel
authors.initials: I
authors.lastname: Cirera
authors.forename: Ricard
authors.initials: R
authors.lastname: Solà
authors.forename: Ana
authors.initials: A
authors.lastname: Bargalló
authors.forename: Rosa Maria
authors.initials: RM
authors.lastname: Morillas
authors.forename: Ramon
authors.initials: R
authors.lastname: Planas
mesh_terms: D000368:Aged; D000428:Alcohol Drinking / Q000009:adverse effects / Q000453:epidemiology; D001201:Ascites / Q000453:epidemiology / Q000209:etiology; D006528:Carcinoma, Hepatocellular / Q000453:epidemiology* / Q000209:etiology; D005260:Female; D005500:Follow-Up Studies; D006501:Hepatic Encephalopathy / Q000453:epidemiology* / Q000209:etiology; D006801:Humans; D008104:Liver Cirrhosis, Alcoholic / Q000150:complications / Q000503:physiopathology*; D008113:Liver Neoplasms / Q000453:epidemiology* / Q000209:etiology; D008297:Male; D008875:Middle Aged; D011446:Prospective Studies; D012720:Severity of Illness Index; D016019:Survival Analysis; D015996:Survival Rate; D013695:Temperance